Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in Type 2 diabetes mellitus

被引:22
|
作者
Qiu-Yue, Wang [1 ]
Fen-Qin, Chen [1 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Endocrinol, Shenyang 110001, Peoples R China
关键词
Diabetes mellitus; Diabetic nephropathy; Monocyte chemoattractant protein-1; KAPPA-B ACTIVATION; MYCOPHENOLATE-MOFETIL; NEPHROPATHY; SPIRONOLACTONE; ASSOCIATION; INJURY; MCP-1;
D O I
10.1016/j.diabres.2008.09.048
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Monocyte chemoattractant protein-1(MCP-1) is a cytokine that exhibits most potent chemotactic activity toward monocytes. It is suggested to be implicated in the development and progression of diabetic nephropathy by playing a role in infiltration of monocyte/macrophage. Recent studies have demonstrated that urinary monocyte chemoattractant protein-1 (uMCP-1) is different at different stages of diabetic nephropathy. Based on these findings, the aim of this study is to examine the level of uMCP-1 and its clinical significance at different stages of diabetic nephropathy and at the same time to describe the relationship between uMCP-1 and the various parameters. Methods: Fifty-nine cases with type 2 diabetes mellitus (T2DM) were divided into three groups according to urine albumin excretion (UAE): normal albuminuria group, microalbuminuria group and macroalbuminuria group. The levels of uMCP-1, protein excretion, blood urea nitrogen (BUN), serum creatinine (s-Cr), glycohemoglobin A1c (HbA1c), blood pressure and blood fat were measured in 59 patients with T2DM and 27 healthy adults as controls. Results Compared with normal control, levels of uMCP-1 in T2DM were significantly high, which were already elevated in normal albuminuria group. Compared with normal albuminuria group, levels of uMCP-1 in microalbuminuria group and macroalbuminuria group were significantly high. Levels of uMCP-1 in macroalbuminuria group were higher than those in microalbuminuria group. The level of uMCP-1 was positively correlated with UAE, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in T2DM patients, while it had no significant correlation with HbA1c, triglyceride (TG) and high density lipoprotein cholesterol (HDL-C). Conclusions: MCP-1 is suggested to be implicated in the development and progression of diabetic nephropathy. it is very important to measure the level of uMCP-1 in the diagnosis and intervention of early diabetic nephropathy. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [31] Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population
    Zakharyan, Roksana
    Boyajyan, Anna
    Arakelyan, Arsen
    Melkumova, Maya
    Mrazek, Frantisek
    Petrek, Martin
    CYTOKINE, 2012, 58 (03) : 351 - 354
  • [32] Association of urinary monocyte chemoattractant protein-1 (MCP-1) and kidney injury molecule-1 (KIM-1) with risk factors of diabetic kidney disease in type 2 diabetes patients
    Siddiqui, Khalid
    Joy, Salini Scaria
    Al-Rubeaan, Khalid
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (08) : 1379 - 1386
  • [33] The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-β, increases podocyte motility and albumin permeability
    Lee, Eun Young
    Chung, Choon Hee
    Khoury, Charbel C.
    Yeo, Tet Kin
    Pyagay, Petr E.
    Wang, Amy
    Chen, Sheldon
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2009, 297 (01) : F85 - F94
  • [34] Chemokine Ligand 2 Genetic Variants, Serum Monocyte Chemoattractant Protein-1 Levels, and the Risk of Coronary Artery Disease
    van Wijk, Diederik F.
    van Leuven, Sander I.
    Sandhu, Manjinder S.
    Tanck, Michael W.
    Hutten, Barbara A.
    Wareham, Nicholas J.
    Kastelein, John J. P.
    Stroes, Erik S. G.
    Khaw, Kay-Tee
    Boekholdt, S. Matthijs
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (07) : 1460 - U466
  • [35] Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy
    Tam, Frederick W. K.
    Riser, Bruce L.
    Meeran, Karim
    Rambow, JoAnn
    Pusey, Charles D.
    Frankel, Andrew H.
    CYTOKINE, 2009, 47 (01) : 37 - 42
  • [36] Monocyte chemoattractant protein-1: does it play a role in diabetic nephropathy?
    Wada, T
    Yokoyama, H
    Matsushima, K
    Kobayashi, K
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (03) : 457 - 459
  • [37] Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity
    Lim, Jun Pei
    Leung, Bernard P.
    Ding, Yew Yoong
    Tay, Laura
    Ismail, Noor Hafizah
    Yeo, Audrey
    Yew, Suzanne
    Chong, Mei Sian
    CLINICAL INTERVENTIONS IN AGING, 2015, 10 : 605 - 609
  • [38] Circulation monocyte chemoattractant protein-1 levels on Wistar Rat induced obesity with high fat diet
    Ridwan, Muhammad
    Natzir, Rosdiana
    Rasyid, Haerani
    Patellongi, Ilhamjaya
    GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2020, 179 (11) : 618 - 624
  • [39] Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans
    Yousefzadeh, Matthew J.
    Schafer, Marissa J.
    Noren Hooten, Nicole
    Atkinson, Elizabeth J.
    Evans, Michele K.
    Baker, Darren J.
    Quarles, Ellen K.
    Robbins, Paul D.
    Ladiges, Warren C.
    LeBrasseur, Nathan K.
    Niedernhofer, Laura J.
    AGING CELL, 2018, 17 (02)
  • [40] Monocyte chemoattractant protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes
    Ismail, Nagwa Abdallah
    Abd El Baky, Abeer N.
    Ragab, Shadia
    Hamed, Mona
    Hashish, Maha Abo
    Shehata, Abed
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2016, 29 (06) : 641 - 645